AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
Era L Pogosova-Agadjanyan1, Anna Moseley2, Megan Othus2
1Clinical Research Division, Fred Hutch, 1100 Fairview Ave N, D5-112, Seattle, WA 98109 USA.
Biomarker Research
|August 21, 2020
Summary
The European LeukemiaNet guidelines are crucial for acute myeloid leukemia (AML) risk stratification. Incorporating age and transcript biomarkers shows potential for improved patient assessment, especially in older adults.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Updated European LeukemiaNet (ELN) guidelines integrate cytogenetic and genetic factors for acute myeloid leukemia (AML) patient triage.
- Few identified prognostic factors are currently used in clinical practice.
Purpose of the Study:
- To develop and validate novel prognostic models to enhance the performance of existing ELN guidelines for AML.
- To assess the impact of age and transcript biomarkers on AML risk stratification.
Main Methods:
- Developed prognostic models using ELN biomarkers, age, performance status, and transcript biomarkers.
- Models were developed and validated on independent cohorts of previously untreated AML patients receiving intensive chemotherapy.
Main Results:
- ELN guideline models showed significant association with clinical outcomes.
- Models including age and select transcripts demonstrated improved predictive accuracy in discovery cohorts.
- Age integration improved risk group separation, particularly in older AML patients.
Conclusions:
- European LeukemiaNet guidelines are essential for AML risk stratification.
- Additional prognostic factors, notably age, are needed to refine AML risk assessment and improve patient outcomes.
Related Concept Videos
01:21Cancer Survival Analysis
564
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
564
01:12Relative Risk
1.5K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
1.5K